The talent, the expertise and the commitment of our scientific teams have made and will continue making RhemaStem the leader in the area of cancer and normal stem cell research for innovative drug discovery in the field of oncology and regenerative medicine.
We offer consulting services in this area with numerous unique platform technologies developed over the last ten years with remarkably wide range of possible applications.
RhemaStem has filed patent applications that if granted substantially as claimed cover the current products and a range of future products. The patent families have been developed and are owned by the Company. The patent applications will be when the time falls due, filed under the Patent Cooperation Treaty (PCT) that allows the making of the applications in most international territories.